Experience approximately 9.5 hours of late-breaking scientific sessions covering timely and novel research on the evolving SARS-CoV-2 pandemic. These sessions include a special presentation on the pandemic from Admiral Brett P. Giroir, who leads the coordination of SARS-CoV-2 testing efforts across the U.S. Department of Health and Human Services, as well as talks on the SARS-CoV-2 vaccine; treatments for COVID-19; SARS-CoV-2 antibody and antigen tests, and more. The recordings of these sessions are perfect for anyone who was not able to attend or for attendees who would like to revisit their favorite sessions.
The recordings include audio and presentation slides from most of the conference’s COVID-19 scientific sessions and will be accessible as streaming content (not as a download).
Once you buy a subscription, you can access the recordings here. You will be able to view the recordings an unlimited number of times from January 19, 2021 through November 30, 2021.
This activity is designed to meet the needs of clinical laboratory professionals, physicians, research scientists, and other professionals from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of progressing laboratory science and medicine.
At the end of this activity, participants will be able to:
- Explain the roles and importance of molecular, antibody, and antigen tests for the diagnosis and control of SARS-CoV-2.
- Discuss the clinical utility of antigen and antibody testing for SARS-CoV-2.
- Describe the results of key clinical trials and studies shaping current COVID-19 treatments.
- Explain the basic biology of SARS-CoV-2 and COVID-19 as it relates to vaccine development.
- Illustrate the laboratory staffing challenges that arise when managing an emerging pathogen.
Special Presentation from Admiral Brett P. Giroir, MD - COVID-19: Past, Present, and Future
- Admiral Brett P. Giroir, MD
SARS-CoV-2 Virology, Kinetics, Diagnostics, and Containment
- Introduction | Patrick Kyle, PhD
- Epidemiology and Biology of SARS-CoV-2 infection | Giuseppe Lippi, MD, PhD
- SARS-CoV-2: Virology and Evolving Diagnostic Paradigms | John R. Hackett
- Panel Discussion
SARS-CoV-2 Vaccine Basics – Current State of Affairs
Therapeutic Strategies for COVID-19
- COVID-19 Drug Trials: What Worked, What Didn’t | Kathleen Mullane, DO, PharmD
- Convalescent Plasma Treatment for COVID-19 | Jill Adamski, MD, PhD
- Prevent the Vent: Foresight or Foolishness? | Allison Dalton, MD
- Panel Discussion
Clinical Laboratory Direction in the Apocalypse: Responding to the SARS-CoV-2 Pandemic in the First Hotspot in the U.S.
- The Clinical Virologist Perspective | Geoffrey Stuart Baird, DABCC
- The Medical Laboratory Perspective | Patrick C. Mathias, MD, PhD
- Panel Discussion
Antibody and Antigen Testing for SARS-CoV-2: Where Are We Now?
- Laboratory Serology & Antigen Testing for SARS-CoV-2: Utility and Limitations | Patricia Raluca Slev, PhD, DABCC
- Update on the Humoral Immune Response to SARS-CoV-2: Antibody Kinetics, Protective Immunity, Vaccines, and Convalescent Plasma Therapy | Elitza S. Theel, PhD, D(ABMM)
DISCLOSURES AND STATEMENT OF INDEPENDENCE
AACC is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all educational activities. All participating planning committee members and faculty are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information on which they can make their own judgments.
All recommendations involving clinical medicine are based on evidence accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients; AND/OR all scientific research referred to or reported in support or justification of a patient care recommendation conforms to generally accepted standards of experimental design, data collection, and analysis.
This activity is approved for 9.5 ACCENT credits. Its activity ID# is 2085. This activity was planned in accordance with ACCENT Standards and Policies.
Release date: 1/19/2021
Credit valid until: 12/31/2023
SUCCESSFUL COMPLETION STATEMENT
Verification of Participation certificates are provided to registered participants based on completion of the activity, in its entirety, and the activity evaluation. For questions regarding continuing education, please email [email protected].